RJA
BLCM

Raymond James & Associates’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Raymond James & Associates’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,373
Closed -$56K – 3778
2019
Q4 		$56K Buy
4,373
+755
+21% +$6.97K ﹤0.01% 3541
2019
Q3 		$38K Buy
3,618
+510
+16% +$6.67K ﹤0.01% 3495
2019
Q2 		$53K Buy
3,108
+42
+1% +$1.14K ﹤0.01% 3499
2019
Q1 		$103K Buy
3,066
+115
+4% +$3.84K ﹤0.01% 3384
2018
Q4 		$86K Buy
2,951
+521
+21% +$23.1K ﹤0.01% 3325
2018
Q3 		$150K Sell
2,430
-1,115
-31% -$75.5K ﹤0.01% 3367
2018
Q2 		$262K Sell
3,545
-52
-1% -$4.05K ﹤0.01% 3106
2018
Q1 		$236K Sell
3,597
-650
-15% -$49.1K ﹤0.01% 3045
2017
Q4 		$357K Sell
4,247
-1,206
-22% -$118K ﹤0.01% 2740
2017
Q3 		$630K Buy
5,453
+1,857
+52% +$195K ﹤0.01% 2350
2017
Q2 		$420K Buy
+3,596
New +$446K ﹤0.01% 2527

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Raymond James & Associates's BLCM Position: Q1 2020 in Review

Raymond James & Associates sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 4,373 shares — an estimated $56K sold.

Raymond James & Associates first reported a position in BLCM in Q2 2017 and held it in 11 quarters. The position peaked at $630K in Q3 2017. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

  • Raymond James & Associates reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Raymond James & Associates sold 4,373 Bellicum Pharmaceuticals, Inc. shares in Q1 2020, an estimated $56K.
  • Raymond James & Associates first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2017 and held it in 11 quarters.
  • Raymond James & Associates's Bellicum Pharmaceuticals, Inc. position peaked at $630K in Q3 2017.
  • 29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.